




CORRECTION OPEN



# Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis

Arleigh McCurdy , Hira Mian , Richard LeBlanc, Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram , Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece and Christopher P. Venner

© The Author(s) 2023

*Blood Cancer Journal* (2023)13:129; <https://doi.org/10.1038/s41408-023-00888-6>

Correction to: *Blood Cancer Journal* (2023) 13:111 <https://doi.org/10.1038/s41408-023-00883-x>, published online 20 July 2023

In Table 2 of this article, the data in the columns headed “ASCT ( $N = 3111$ )” and “Non-ASCT ( $N = 2437$ )” were assigned in incorrect lines. Correct Table 2 is as follows:

**Table 2.** Multivariable model showing factors associated with attrition at each line of therapy by ASCT status.

LOT	Predictors	ASCT (N = 3111) OR (95% CI)	Non-ASCT (N = 2437) OR (95% CI)
1	Sex:		
	Female	Ref	Ref
	Male	<b>1.33 (1.00–1.78)</b>	1.20 (0.96–1.49)
	Age <sup>a</sup> :		
	<65	Ref	Ref
	65–74	<b>1.56 (1.16–2.09)</b>	0.95 (0.68–1.31)
	75–84	0 (0–Inf)	<b>1.54 (1.11–2.13)</b>
	>=85	0 (0–Inf)	<b>3.57 (2.38–5.35)</b>
	Cohort:		
	2010–2015	Ref	Ref
	2016–2020	<b>0.45 (0.33–0.63)</b>	<b>0.70 (0.56–0.87)</b>
	Progression time (m):		
	≥24	Ref	Ref
	12–24	<b>1.59 (1.10–2.31)</b>	<b>0.54 (0.38–0.79)</b>
	6–12	<b>2.81 (1.71–4.63)</b>	1.32 (0.94–1.86)
<6	1.10 (0.51–2.36)	<b>3.45 (2.54–4.70)</b>	
Response:			
<PR	Ref	Ref	
≥PR	0.61 (0.35–1.08)	<b>0.75 (0.56–1.00)</b>	
2	Sex:		
	Female	Ref	Ref
	Male	<b>1.44 (1.02–2.02)</b>	<b>1.40 (1.08–1.81)</b>
	Age <sup>a</sup> :		
	<65	Ref	Ref
	65–74	<b>1.44 (1.01–2.07)</b>	1.01 (0.68–1.50)
	75–84	0 (0–Inf)	1.20 (0.80–1.79)
	>=85	0 (0–Inf)	<b>2.97 (1.72–5.15)</b>
	Cohort:		
	2010–2015	Ref	Ref
	2016–2020	0.97 (0.68–1.40)	<b>0.72 (0.55–0.94)</b>
	Progression time (m):		
	≥24	Ref	Ref
	12–24	1.52 (0.83–2.76)	1.20 (0.81–1.77)
	6–12	<b>2.00 (1.17–3.43)</b>	1.34 (0.89–2.01)
<6	<b>4.63 (3.07–7.00)</b>	<b>2.48 (1.78–3.46)</b>	
Response:			
<PR	Ref	Ref	
≥PR	1.40 (0.91–2.17)	0.76 (0.55–1.04)	
Gender: Female	Ref	Ref	
Male	1.11 (0.78–1.58)	1.13 (0.81–1.58)	
3	Age <sup>a</sup> :		
	<65	Ref	Ref
	65–74	<b>1.78 (1.20–2.62)</b>	0.98 (0.60–1.62)
	75–84	0 (0–Inf)	1.04 (0.62–1.73)
	>=85	0 (0–Inf)	2.32 (0.92–6.01)
	Cohort:		
	2010–2015	Ref	Ref
	2016–2020	1.13 (0.74–1.72)	0.92 (0.64–1.31)
	Progression time (m):		
	≥24	Ref	Ref
	12–24	1.08 (0.51–2.27)	<b>3.12 (1.74–5.59)</b>
	6–12	1.62 (0.92–2.84)	<b>2.44 (1.41–4.23)</b>
	<6	<b>2.80 (1.73–4.51)</b>	<b>3.94 (2.48–6.27)</b>
	Response:		
	<PR	Ref	Ref
≥PR	0.90 (0.90–1.37)	<b>0.57 (0.38–0.86)</b>	

Values bolded  $p < 0.05$ .<sup>a</sup>Age at therapy initiation.

The original article has been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023